CA Patent

CA2295620A1 — 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection

Assigned to Boehringer Ingelheim Pharmaceuticals Inc · Expires 1999-02-18 · 27y expired

What this patent protects

Disclosed are novel heteroaryl-dipyridoazepines. These are useful in the prevention or treatment of HIV infection.

USPTO Abstract

Disclosed are novel heteroaryl-dipyridoazepines. These are useful in the prevention or treatment of HIV infection.

Drugs covered by this patent

Patent Metadata

Patent number
CA2295620A1
Jurisdiction
CA
Classification
—
Expires
1999-02-18
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.